No Data
No Data
Tonghua Golden-Horse Pharmaceutical Industry Co, Ltd (000766.SZ): The developed Amber Octahydroaminoacridine Tablets have completely independent intellectual property rights and are a Class I new drug at the national level.
Tonghua Golden-Horse (000766.SZ) stated on its investor platform on July 30th that our company's amber octahydroammine metronidazole tablets are a first-class new drug at the national level with completely independent intellectual property rights. The application of the active pharmaceutical ingredient for listing is an important part of the new drug listing application. Currently, the company is strictly following the relevant laws, regulations, and guidance principles of the CDE to carry out work related to the new drug listing application.
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (000766.SZ) developed Amber tinapentine hydrochloride tablets mainly for the treatment of mild to moderate Alzheimer's disease.
On July 29, Gelunhui reported that Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (SZ 000766) stated on the investor interaction platform that their research on Amber Octahydroaminoacridine tablets is mainly used to treat mild to moderate Alzheimer's disease.
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (000766.SZ) has established comprehensive patent protection measures for its new drugs.
On July 25th, Gelunhui reported that an investor asked Tonghua Golden-horse Pharmaceutical Industry Co., Ltd. (000766.SZ) on the investor interactive platform, "How long is the patent for the company's new drug?" The company responded that it has established a comprehensive patent protection strategy for the new drug. Please refer to relevant official channels for specific patent information.
Tonghua Golden-horse Pharmaceutical Industry Co.,Ltd(000766.SZ): Received the amber octahydroaminoacridine market application registration acceptance notice.
On July 24th, Gelunhui reported that Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (000766.SZ) announced that the company recently received an "Acceptance Notice" for the application registration of amber octahydroaminoacridine issued by the National Medical Products Administration. Amber octahydroaminoacridine is the active pharmaceutical ingredient of amber octahydroaminoacridine tablets, and our company has independent intellectual property rights. Amber octahydroaminoacridine tablet is a new type I national-level innovative drug with completely independent intellectual property rights developed by our company. It is a novel acetylcholinesterase inhibitor with dual acetylcholinesterase inhibition function. It is mainly used to treat mild to moderate Alzheimer's disease.
Subdued Growth No Barrier To Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd's (SZSE:000766) Price
Tonghua Golden-horse Pharmaceutical Industry Co., Ltd. (000766.SZ): Amber Octahydroaminoacridine Tablets will submit a new drug application to the Center for Drug Evaluation.
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (000766.SZ) stated on its investor interaction platform on July 2nd that the new drug Amber Octahydroaminoisquinoline Tablets has completed unblinding, statistical analysis report, clinical trial summary report, and the next step is to submit a new drug application for marketing to the Center for Drug Evaluation (CDE). Currently, the company is progressing normally according to the established work plan in accordance with relevant requirements of CDE.
No Data